Intelligent Bio Solutions Inc. (INBS)
NASDAQ:INBS
INBS Stock Chart & Stats
$1.03
-$0.03(-2.02%)
At close: 4:00 PM EST
$1.03
-$0.03(-2.02%)
Day’s Range― - ―
52-Week Range$3.18 - $24.90
Previous CloseN/A
Volume32.28K
Average Volume (3M)96.60K
Market Cap
$6.80M
Enterprise Value$4.91M
Total Cash (Recent Filing)$740.37K
Total Debt (Recent Filing)$3.45M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding2,001,173
10 Day Avg. Volume48,787
30 Day Avg. Volume96,602
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda-0.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing Partnership & ScaleThe Syrma Johari manufacturing partnership materially increases capacity (~4x) and targets >40% production cost savings and ~20 percentage points of gross margin improvement. Those structural cost and scale advantages can sustainably improve unit economics and gross margins as volumes ramp.
Expanded Capacity And Vertical IntegrationDeployment of readers in UK/Europe, larger installed base, doubled in-house lateral flow strip production and increased inventory/R&D throughput create durable revenue leverage. Deeper vertical integration supports recurring consumable sales and reduces supplier risk over the next several quarters.
Capital Raise And Manageable LeverageA $10M strategic financing plus a low debt-to-equity ratio (~0.17) provide near-term liquidity and flexibility. The stronger equity base and modest leverage reduce immediate balance-sheet risk and support ongoing regulatory and commercialization investments over the medium term.
Bears Say
Persistent Cash BurnOperating cash flow and free cash flow remain significantly negative (~-$9.4M and -$9.7M TTM), indicating the business is not yet self-funding. Continued cash burn requires external capital and constrains the timeline to sustainable profitability if commercialization or margin gains are delayed.
Very Weak ProfitabilityDespite revenue growth and solid gross margin, operating and net losses remain very large (net margin ~-315% TTM). The current cost structure is far out of line with revenue, meaning the company needs substantial margin expansion or scale to reach breakeven, a multi-quarter structural challenge.
Ongoing Equity Dilution RiskManagement has issued equity awards and maintains ATM capacity while recently using equity financings, signaling reliance on equity to fund operations. Persistent capital raises and share issuances create dilution risk and reflect structural funding dependence until cash flow turns sustainably positive.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions Inc.’s price range in the past 12 months?
Intelligent Bio Solutions Inc. lowest stock price was $3.18 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions Inc.’s market cap?
Intelligent Bio Solutions Inc.’s market cap is $6.80M.
When is Intelligent Bio Solutions Inc.’s upcoming earnings report date?
Intelligent Bio Solutions Inc.’s upcoming earnings report date is May 13, 2026 which is in 47 days.
How were Intelligent Bio Solutions Inc.’s earnings last quarter?
Intelligent Bio Solutions Inc. released its earnings results on Feb 12, 2026. The company reported -$2.82 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.82.
Is Intelligent Bio Solutions Inc. overvalued?
According to Wall Street analysts Intelligent Bio Solutions Inc.’s price is currently Overvalued.
Does Intelligent Bio Solutions Inc. pay dividends?
Intelligent Bio Solutions Inc. does not currently pay dividends.
What is Intelligent Bio Solutions Inc.’s EPS estimate?
Intelligent Bio Solutions Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intelligent Bio Solutions Inc. have?
Intelligent Bio Solutions Inc. has 2,001,173 shares outstanding.
What happened to Intelligent Bio Solutions Inc.’s price movement after its last earnings report?
Intelligent Bio Solutions Inc. reported an EPS of -$2.82 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions Inc.?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
― Insiders
0.36% Mutual Funds
0.01% Other Institutional Investors
99.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---